ABAliyah Baluch

Aliyah Baluch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aliyah Baluch has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disseminated Toxoplasmosis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient: A Case Report and Review of the Current Literature

    by Aliyah Baluch, Guy Handley, Steven Ludlow, Austin Morrison, Ana Velez, Marcia C. Rojas, Yanina Pasikhova

    Reactivation infections in hematopoietic stem cell transplants are mitigated by prophylactic regimens. Despite high rates of exposure, morbidity and mortality secondary to toxoplasmosis are limited to subsets of patients such as immunocompromised persons. We describe the first case of disseminated toxoplasmosis in a double umbilical cord blood transplant recipient.


  • Open Access

    Infectious Complications of DiGeorge Syndrome in the Setting of Malignancy

    by Heather Hare, Pragya Tiwari, Aliyah Baluch, John Greene

    This report describes a case of a young man with DiGeorge Syndrome, repaired Tetralogy of Fallot, relapsed metastatic Hodgkin’s Lymphoma, immunodeficiency, and a history of recurrent and severe infections. A review of the literature indicates that patients with DiGeorge Syndrome are at greater risk for infection, malignancy, and cardiac events due to anatomic and immunologic complications resulting from a deletion in the 22q11.2 chromosome. As an increased number of patients with DiGeorge Syndrome are surviving into adulthood, it is important to understand the progression of the disease and the long-term implications associated with variable degrees of thymic hypoplasia and immune deficiency.


  • Neutropenic Fever

    by Aliyah Baluch, Sarah Shewayish

    Neutropenia is defined as an abnormally low absolute neutrophil count (ANC) and can be further delineated as severe or profound (see below). Recipients of chemotherapy will often have a decreased ANC leading to an increased risk of infections specifically from bacterial sources. Neutropenia traditionally is risk stratified based on duration and depth of neutropenia. Recipients of chemotherapy for acute myelogenous leukemia (AML) and stem cell transplants (SCTs) often are deemed as having high risk neutropenia due to significant depth and duration of neutropenia. The mortality associated with febrile neutropenia is up to 11%, and can be as high as 50% in the setting of severe sepsis or septic shock. By risk stratifying neutropenia and the resultant neutropenic fever, the goal is to decrease the resultant morbidity and mortality (Taplitz et al., J Clin Oncol 36:3043–3054).


  • Open Access

    Fever in Patients with Cancer

    by Yanina Pasikhova, Steven Ludlow, Aliyah Baluch

    The definition of fever is flexible and depends on the clinical context. Fever is frequently observed in patients with cancer. Infectious and noninfectious causes of fever in patients with various oncological and hematological malignancies and the usefulness of biomarkers are discussed. To treat patients in a timely manner and to minimize morbidity and mortality, it is paramount that health care professionals determine the cause of fever. The usefulness of biomarkers in febrile patients with cancer continues to be controversial. Fever is frequently seen in patients with cancer and can be associated with a variety of infectious and noninfectious causes. The utility of acute-phase reactants, such as erythrocyte sedimentation rate, C-reactive protein, and procalcitonin, along with a nonsteroidal anti-inflammatory drug challenge should be further evaluated as adjunct tools for the workup of fever in patients with cancer.


  • Influenza Vaccination in Oncology Patients

    by Aliyah Baluch, Yanina Pasikhova

    It is well established that the immunological response to the seasonal trivalent influenza vaccine is attenuated in cancer patients. Furthermore, rates of seroprotection and seroconversion vary by malignancy type and are higher in patients with solid tumors, as compared either with those with hematologic malignancies or with allogeneic hematopoietic stem cell recipients. In 2009, a novel influenza strain prompted development of new vaccines and evaluation of alternative dosing strategies in an attempt to increase the rates of seroconversion in immunocompromised patients, further complicating this issue. Recent literature has demonstrated that the use of myeloablative chemotherapy regimens and biologics is correlated with decreased immunogenicity and response to influenza vaccines. Much debate still exists as to the optimal timing of influenza vaccination. Delaying vaccination from 1 week following standard chemotherapy up to 6 months following rituximab is increasingly supported by studies in this heterogeneous population.